I have been asked several questions about the #ASCO23 abstract:  
Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study (8034), wanted to create a 🧵 for #mmsm… twitter.com/i/web/status/1… What were the criteria for switching to less frequent dosing schedules?
• In phase 1, patients had the option to switch from weekly to Q2W (every other week) dosing if they had achieved at least a partial response and at least 4 cycles of treatment
• In phase 2, patients had… twitter.com/i/web/status/1…

Bispecific antibodies are showing unprecedented single agent activity in relapsed/refractory MM. There are several phase I trials in this setting, let’s see at the data shared at #ASCO22 and #EHA2022 with Teclistamab , Elranatamab and REGN5458 targeting BCMA and… ….Talquetamab targeting GPRC5D. Here is a quick summary of the data #CARTSM #ASCO22_SZU #MedIQ22ASCO Strong work by #mmsm peeps!!

1/For this #ASH21 'Best of Abstracts' selection, I asked my @sloan_kettering #mmsm service team members for top 5 abstracts in different categories. Please follow the thread below for the #ASH21_MSKMM selections: 2/Top 5 Basic/Translational
-ash.confex.com/ash/2021/webpr…
- ash.confex.com/ash/2021/webpr…
- ash.confex.com/ash/2021/webpr…
- ash.confex.com/ash/2021/webpr…

1/7 Lots to unroll on #ASH20SU #ASH20 #mmsm abstracts, will do in several categories:

TOP TRANSLATIONAL
-ImmunoCell Study (ash.confex.com/ash/2020/webpr…)
-Discordance btwn IFE and MRD (ash.confex.com/ash/2020/webpr…)
@theMMRF @IMFmyeloma @Myeloma_Society @ASH_hematology 2/7 #ASH20SU #ASH20 #mmsm
-Immune ME Changes from MGUS/SMM to active MM (ash.confex.com/ash/2020/webpr…)
-PCL Genome/Transcriptome (ash.confex.com/ash/2020/webpr…)
-Resistance to BCMA Therapy (ash.confex.com/ash/2020/webpr…)
-Immunogenomic heterogeneity in MM (ash.confex.com/ash/2020/webpr…)

The chromosome 1q21 story (1/10):
-Having extra copies of generally odd num. chromosomes constituents hyperdiploidy #mmsm , recognized as ‘HY’ in GEP based molecular classification.
-Having 3 copies is called ‘gain 1q21’
-Having >=4 copies is called ‘amplification of 1q21’. The chromosome 1q21 story (2/10):
-Herve Avet-Louiseau identifies 1q21 ‘enhancement’ in human MM cell lines, primary MM cells and plasma cell leukemia (PMID: 9172003), Shaughnessy et al corroborate (PMID: 15472896).
- Gain/Amp ch. 1q21 first recognized as poor prognostic markers